首页> 外文期刊>European journal of internal medicine >The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system
【24h】

The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system

机译:靶向外周内吲哚尼蛋白/ CB1受体系统的治疗潜力

获取原文
获取原文并翻译 | 示例
           

摘要

Endocannabinoids (eCBs) are internal lipid mediators recognized by the cannabinoid-1 and -2 receptors (CB1R and CB2R, respectively), which also mediate the different physiological effects of marijuana. The endocannabinoid system, consisting of eCBs, their receptors, and the enzymes involved in their biosynthesis and degradation, is present in a vast number of peripheral organs. In this review we describe the role of the eCB/CB1R system in modulating the metabolism in several peripheral organs. We assess how eCBs, via activating the CB1R, contribute to obesity and regulate food intake. In addition, we describe their roles in modulating liver and kidney functions, as well as bone remodeling and mass. Special importance is given to emphasizing the efficacy of the recently developed peripherally restricted CB1R antagonists, which were pre-clinically tested in the management of energy homeostasis, and in ameliorating both obesity-and diabetes-induced metabolic complications.
机译:Endocannaboids(ECB)是由大麻素-1和-2受体(CB1R和CB2R)识别的内部脂质介质(分别为CB1R和CB2R),其也介导大麻的不同生理作用。 由ECBS,其受体和参与其生物合成和降解的酶组成的内胆碱系统存在于大量外周器官中。 在本次综述中,我们描述了ECB / CB1R系统在多个外围器官中调制新陈代谢的作用。 我们评估ECBS如何通过激活CB1R,有助于肥胖和调节食物摄入量。 此外,我们描述了调节肝肾功能以及骨骼重塑和质量方面的作用。 特别重要的是强调最近发育的外周限制的CB1R拮抗剂的功效,这在能量稳态和改善肥胖和糖尿病诱导的代谢并发症中进行预临临床测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号